EHC SUPPLY - Søgeresultater

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

sehcat kapsler

ge healthcare buchler gmbh . & co kg - selen(75-se)-tauroselcholinsyre - kapsler

Den Europæiske Union - dansk - EMA (European Medicines Agency)

jayempi

nova laboratories ireland limited - azathioprine - graft afvisning - immunosuppressiva - jayempi is indicated in combination with other immunosuppressive agents for the prophylaxis of transplant rejection in patients receiving allogenic kidney, liver, heart, lung or pancreas transplants. azathioprine is indicated in immunosuppressive regimens as an adjunct to immunosuppressive agents that form the mainstay of treatment (basis immunosuppression). jayempi is used as an immunosuppressant antimetabolite either alone or, more commonly, in combination with other agents (usually corticosteroids) and/ or procedures which influence the immune response. jayempi is indicated in patients who are intolerant to glucocorticosteroids or if the therapeutic response is inadequate despite treatment with high doses of glucocorticosteroids, in the following diseases:severe active rheumatoid arthritis (chronic polyarthritis) that cannot be kept under control by less toxic agents (disease-modifying anti-rheumatic -medicinal products – dmards)auto-immune hepatitis systemic lupus erythematosusdermatomyositispolyarteritis nodosapemphigus vulgaris and bullous pemphigoidbehçet’s diseaserefractory auto-immune haemolytic anaemia, caused by warm igg antibodieschronic refractory idiopathic thrombocytopenic purpurajayempi is used for the treatment of moderately severe to severe forms of chronic inflammatory bowel disease (ibd) (crohn’s disease or ulcerative colitis) in patients in whom glucocorticosteroid therapy is necessary, but where glucocorticosteroids are not tolerated, or in whom the disease is untreatable with other common means of first choice. it is also indicated in adult patients in relapsing multiple sclerosis, if an immunomodulatory therapy is indicated but beta interferon therapy is not possible, or a stable course has been achieved with previous treatment with azathioprine. 3jayempi is indicated for the treatment of generalised myasthenia gravis. depending on the severity of the disease, jayempi should be given in combination with glucocorticosteroids because of slow onset of action at the beginning of treatment and the glucocorticosteroid dose should be gradually reduced after several months of treatment.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

otezla

amgen europe bv - apremilast - arthritis, psoriatic; psoriasis - immunosuppressiva - psoriasis arthritisotezla, alene eller i kombination med sygdomsmodificerende antireumatiske lægemidler (dmard), er indiceret til behandling af aktiv psoriasis artrit (psa) hos voksne patienter, der har haft et utilstrækkeligt respons eller som har været intolerant over for en forudgående dmard behandling. psoriasisotezla er indiceret til behandling af moderat til svær kronisk plaque psoriasis hos voksne patienter, der har undladt at reagere på, eller som har en kontraindikation til, eller er intolerante over for andre systemisk terapi, herunder ciclosporin, methotrexat eller psoralen og ultraviolet-lys (puva).

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

sandimmun neoral 100 mg kapsler, bløde

orifarm a/s - ciclosporin - kapsler, bløde - 100 mg

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

sandimmun neoral 50 mg kapsler, bløde

orifarm a/s - ciclosporin - kapsler, bløde - 50 mg

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

sandimmun neoral 100 mg/ml oral opl?sning

orifarm a/s - ciclosporin - oral opløsning - 100 mg/ml

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

ciclosporin "actavis" 100 mg kapsler, bløde

actavis group ptc ehf. - ciclosporin - kapsler, bløde - 100 mg